UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.
Advocate general Henrik Saugmandsgaard Øe has advised Europe’s highest court on the scope of protection held by owners of plant variety rights.
The Court of Justice of the European Union last week issued its decision in a case concerning whether a ‘launch at risk’ bars compensation for a wrongfully issued preliminary injunction.
The world's ”largest genetics project” to tackle deadly diseases was launched yesterday, September 11, supported by funding from the UK government, charities and four pharmaceutical companies.
Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Indian drugmaker Lupin and German pharma company Boehringer Ingelheim have formed an alliance to develop a therapy for patients with difficult-to-treat cancers.
Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.
Nicole Jadeja, the former co-head of life sciences at Fieldfisher, has joined Pinsent Masons as a partner in its London office.
A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.
Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.